Ann: MDR March 2018 Quarterly Report & Appendix 4C, page-6

Modest numbers but still a positive update.

Only $70k increase in revenue between December and March.
- March 2018 Revenue - $1.67M
- December 2017 Revenue - $1.6M

$11M cash to chase domestic and international (US and UK) opportunities.

That's quite a war chest. Management could take out any number of local public or private healthcare groups with that.

The EBOS agreement was estimated to add $4M revenue over the next 3 years.

The sooner this is integrated, the sooner we can start banking the money going forward.

I expect in FY19, all quarterlies will show $2M+ revenue and quickly reaching cash flow positive ($2.7M).

We are working closely with Zest and have implemented a pilot pharmacy and patient engagement program as a forerunner to finalising our commercial agreement.

Discussions with TWCM are well advanced and we expect to finalise the commercial agreement shortly.

I believe the market is waiting for some more detail on this before we climb again. By the sounds of it, it's not far off - despite the announcement in October suggesting it should be binding by December 2017.